Joe Speer
Psychiatry · Tulsa, OKNPI 1467475491
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 355 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,027 and has fallen 98.6% since, to $28 in 2025. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$759
- Corium, LLC$693
- Takeda Pharmaceuticals U.S.A., Inc.$466
- plus $2K from 18 others
What the payments were for
- Food & beverage$7,23799%
- Education$941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 55 | $1,143 |
| Johnson & Johnson | 41 | $1,089 |
| Teva Pharmaceuticals USA, Inc. | 38 | $1,042 |
| AbbVie | 50 | $759 |
| Corium, LLC | 31 | $693 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $466 |
| Lundbeck LLC | 28 | $431 |
| Vanda Pharmaceuticals Inc. | 19 | $346 |
| Noven Therapeutics, LLC | 14 | $255 |
| Supernus Pharmaceuticals, Inc. | 11 | $197 |
| Idorsia Pharmaceuticals US Inc | 9 | $159 |
| Axsome Therapeutics, Inc. | 7 | $154 |
| Bausch Health US, LLC | 7 | $153 |
| Ironshore Pharmaceuticals Inc. | 6 | $112 |
| Adlon Therapeutics L.p. | 4 | $66 |
| Sunovion Pharmaceuticals Inc. | 3 | $65 |
| Alkermes, Inc. | 2 | $49 |
| Almatica Pharma LLC | 2 | $40 |
| Eisai Inc. | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Neuronetics, Inc. | 1 | $15 |
| Tris Pharma Inc | 1 | $14 |
| Avion Pharmaceuticals | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,332 in reported general payments places this provider in the 90th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 27 | $45,747 |
| TrintellixVortioxetine Hydrobromide | 29 | $20,656 |
| VraylarCariprazine Hcl | 15 | $19,792 |
| AdderallDextroamphetamine/Amphetamine | 14 | $13,600 |
| VyvanseLisdexamfetamine Dimesylate | 32 | $12,074 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 239 | $10,807 |
| BelsomraSuvorexant | 12 | $5,472 |
| Alprazolam | 538 | $5,108 |
| Duloxetine Hcl | 96 | $2,612 |
| Lisdexamfetamine Dimesylate | 14 | $2,317 |
| Amphetamine Sulfate | 11 | $2,185 |
| Methylphenidate Hcl | 62 | $2,059 |
| Quetiapine Fumarate | 72 | $1,957 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 24 | $1,806 |
| Bupropion XlBupropion Hcl | 61 | $1,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall, Vyvanse | $466 | $46,33075 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,143 | $45,74727 claims |
| AbbVieVraylar | $759 | $19,79215 claims |
| Almatica Pharma LLCSertraline Hcl | $40 | $38054 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Tulsa
- Sarah LandTulsa$287K
- Bradley McClureTulsa$15K
- Katrina CraderTulsa$15K
- Jeffrey CatesTulsa$11K
- Kaitlin CoresTulsa$10K
- Charles van TuylTulsa$9K
- Michael DubriwnyTulsa$8K
- Martin PaulusTulsa$7K
- Kari YoumanTulsa$5K
- Stevan LahrTulsa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.